Galimi Francesco 4

What Happened Francesco Galimi, CMO & Head of Development and a director at Genenta Science (GNTA), was granted a 20,000-share derivative award on March 30, 2026. The Form 4 records the acquisition price as $0.00 (derivative instrument) — this was a grant/award, not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-03-30; Form 4 filed 2026-04-01 (filed within the standard 2-business-day window).
• Transaction type/code: Award/Grant (A), recorded as a derivative.
• Amount and price: 20,000 shares at $0.00 (acquired value shown as $0 on the filing).
• Vesting: Footnote F1 — the options vest in equal monthly installments over one year beginning March 30, 2026.
• Shares owned after transaction: Not specified in this Form 4.
• No 10b5-1 plan, tax-withholding, or cashless-exercise indicated in the filing.

Context This is a time‑based equity grant (options/award) that vests monthly over 12 months; no shares were sold and no cash changed hands at grant. Such awards align compensation with future service and do not by themselves indicate immediate insider buying or selling.